CDSCO flags one spurious drug, 220 NSQ samples in August surveillance
The Central Drugs Standard Control Organisation found one spurious and 220 not of standard quality (NSQ) drug samples among those tested randomly in its August drug surveillance exercise, according to an alert issued on Tuesday. Central Drugs Laboratories identified 29 of the failed samples and State Drugs Testing Laboratories 191. The spurious sample, from Delhi, was allegedly made by unauthorised manufacturers using another company's brand name. CDSCO said the matter is under investigation.
Source
Hindustan Times — India · read the original report ↗
Desk check · compared with the source
What the desk checked (5)
- CDSCO found one spurious and 220 NSQ drug samples in its August surveillance exercise. — Attributed to CDSCO's NSQ and Spurious Drug Alert issued on Tuesday; figures appear in source.
- Of the failed samples, 29 were identified by Central Drugs Laboratories and 191 by State Drugs Testing Laboratories. — Figures appear twice in source and add up to 220; internally consistent.
- One sample from the National Capital Territory of Delhi was identified as spurious, allegedly made by unauthorised manufacturers using another company's brand name. — Attributed to the CDSCO report; described as allegation with investigation pending.
- Only about 1.5% of sampled drugs were found less efficacious in recent surveys. — Attributed to Drugs Controller General of India Rajeev Singh Raghuvanshi in earlier remarks; no survey document cited.
- The reference to 'August 2026' for the laboratory breakup. — Appears in source text but conflicts with the report's general August framing; sourcing unclear, verify with CDSCO portal.
Analysts’ view opinion
Publishing the NSQ list every month is a genuine transparency gain — a regulatory culture that discloses failures rather than burying them. But the design is inherently limited: sampling-based surveillance catches defective batches only after they have reached distribution points and, in many cases, patients. That 191 of the 220 NSQ findings came from State laboratories shows the Centre-State architecture is functioning, while also underlining that the burden of enforcement sits largely with the States.
- The chosen policy instrument — identify, disclose, withdraw — leans on information transparency rather than deterrence, which helps stakeholders but does not by itself change manufacturer behaviour.
- The single spurious drug, allegedly made by unauthorised manufacturers using another company's brand name, is a criminal supply-chain problem rather than a quality-control lapse, and needs investigative and prosecutorial capacity, not more lab tests.
- The 29-versus-191 split between central and State laboratories suggests outcomes will vary with uneven State testing capacity and speed of follow-up action.
- CDSCO's clarification that a failure applies only to the tested batch is responsible risk communication, but balancing public confidence against industry reputation remains a delicate line.
- The roughly 1.5% failure rate cited earlier by the DCGI offers context, yet the story gives no denominator for August or any count of batches actually recalled — the metrics that would show whether the system works.
What to watch — Watch where the Delhi spurious-drug investigation leads, how many cases actually hold up under the Drugs and Cosmetics Act, and how quickly flagged batches are pulled from the market.
The story does not establish how many samples were tested in total, which drugs or firms are involved, how this compares with previous months, or what action followed earlier alerts.
Deep dive
Research brief · 8 facts · 3 dates · exam-readyThe brief
Context
The Central Drugs Standard Control Organisation (CDSCO), India's central drug regulator, conducts monthly risk-based surveillance in which drug samples are picked randomly from sales and distribution points and tested in government laboratories. Samples failing one or more quality parameters are listed as "not of standard quality" (NSQ), while products made by unauthorised manufacturers or misrepresented are flagged as spurious. The results are published every month on the CDSCO portal as an NSQ and Spurious Drug Alert. The latest alert, issued on Tuesday, reported one spurious sample and 220 NSQ samples from the August surveillance exercise.
Key facts
- CDSCO's alert, issued on Tuesday, flagged 1 spurious drug sample and 220 NSQ drug samples from the August drug surveillance exercise.
- Of the failed samples, 29 were identified by Central Drugs Laboratories and 191 by State Drugs Testing Laboratories (for August 2026, as per the report).
- The single spurious sample came from the National Capital Territory of Delhi.
- The spurious drug was allegedly manufactured by unauthorised manufacturers using a brand name owned by another company; the matter is under investigation.
- Action on the spurious drug will be taken under the Drugs and Cosmetics Act and Rules, CDSCO said.
- NSQ means failure to meet quality standards or specifications, including labelling, dissolution, weight uniformity and sterility.
- Adulterated or spurious drugs are considered capable of causing serious adverse reactions and even death.
- Drugs Controller General of India Rajeev Singh Raghuvanshi earlier said only around 1.5% of total drugs sampled were found less efficacious in recent surveys.
Timeline
- Earlier (date not stated in the source)DCGI Rajeev Singh Raghuvanshi said CDSCO was taking all measures to drastically reduce less efficacious drugs, which were around 1.5% of samples in recent surveys.
- August (surveillance month; report refers to August 2026)Random sampling and testing of drug samples by Central Drugs Laboratories and State Drugs Testing Laboratories.
- Tuesday (date not stated in the source)CDSCO issues its NSQ and Spurious Drug Alert: 1 spurious and 220 NSQ samples; Delhi spurious case under investigation.
Who has a stake
- CDSCO (central drug regulator) — Must identify and remove NSQ and spurious medicines from the market and publish monthly alerts on its portal.
- Central Drugs Laboratories — Government testing labs that identified 29 of the failed samples in the August exercise.
- State Drugs Testing Laboratories / State drug regulators — Identified 191 NSQ samples; surveillance is conducted in collaboration with State regulators.
- Drugs Controller General of India, Rajeev Singh Raghuvanshi — Heads the regulator and has publicly committed to reducing the share of less efficacious drugs.
- Patients and consumers — Risk of serious adverse reactions or death from spurious drugs and reduced efficacy from NSQ batches.
- Pharmaceutical companies whose brand names are misused — Brand reputation and market trust at risk from unauthorised manufacturers copying their brand names.
- Unauthorised manufacturers in the Delhi case — Face investigation and action under the Drugs and Cosmetics Act and Rules.
Why it matters
Spurious and substandard medicines directly endanger patients, since such products can cause serious adverse reactions and even death, and they erode confidence in India's large pharmaceutical sector. The monthly alerts show a working, if limited, surveillance mechanism: batch-specific findings routed through central and State laboratories, with enforcement under the Drugs and Cosmetics Act. That 191 of 220 failures were caught by State labs underlines that drug quality control in India depends heavily on centre-State coordination.
UPSC angle
Prelims pointers
- CDSCO is India's central drug regulator; it publishes an NSQ and Spurious Drug Alert on its portal every month.
- August surveillance: 220 NSQ samples (29 by Central Drugs Laboratories, 191 by State Drugs Testing Laboratories) and 1 spurious sample.
- The lone spurious sample was from the NCT of Delhi, allegedly made by unauthorised manufacturers using another company's brand name.
- Action against spurious and NSQ drugs is taken under the Drugs and Cosmetics Act and Rules.
- Drugs Controller General of India: Rajeev Singh Raghuvanshi; he cited about 1.5% of sampled drugs as less efficacious in recent surveys.
- NSQ parameters include labelling, dissolution, weight uniformity and sterility.
Mains framing
The August CDSCO alert — one spurious and 220 NSQ samples, with 191 failures detected by State laboratories against 29 by Central Drugs Laboratories — illustrates both the reach and the limits of India's drug quality surveillance. Causes of substandard medicines range from manufacturing and storage lapses affecting parameters such as dissolution, weight uniformity, sterility and labelling, to outright criminal activity, as in the Delhi case where unauthorised manufacturers allegedly used another company's brand name. The implications are twofold: a direct patient-safety risk, since spurious and adulterated drugs are held capable of causing serious adverse reactions and even death, and a reputational risk for Indian pharmaceuticals. CDSCO's response rests on continuous risk-based sampling from sales and distribution points, monthly public disclosure to alert stakeholders to specific failed batches, collaboration with State drug regulators for market withdrawal, and prosecution under the Drugs and Cosmetics Act and Rules. The regulator stresses that findings are batch-specific and do not imply wider market concerns, while the DCGI has said only about 1.5% of sampled drugs were found less efficacious recently. A credible way forward, on the source's own logic, lies in strengthening State testing laboratory capacity, faster investigation and action in spurious-drug cases, and sustained public disclosure so that stakeholders can act on flagged batches.
Key terms
- CDSCO
- Central Drugs Standard Control Organisation, India's national drugs regulator, which conducts surveillance and publishes monthly NSQ and spurious drug alerts.
- NSQ (Not of Standard Quality)
- A drug sample that fails one or more specified quality standards, such as labelling, dissolution, weight uniformity or sterility.
- Spurious drug
- A quality-defective product such as one made by unauthorised manufacturers using another company's brand name; can cause serious adverse reactions or death.
- Central Drugs Laboratories
- Central government testing laboratories; identified 29 NSQ samples in the August exercise.
- State Drugs Testing Laboratories
- State-level government drug testing labs; identified 191 NSQ samples in the August exercise.
- Drugs and Cosmetics Act and Rules
- The legal framework under which action is taken against NSQ, adulterated and spurious drugs in India.
Practice questions
- Examine the institutional architecture of drug quality regulation in India. How does the division of work between central and State testing laboratories, as reflected in CDSCO's monthly alerts, affect enforcement outcomes?
- Spurious drugs are described as capable of causing serious adverse reactions and even death. Discuss the public health and regulatory challenges in detecting and removing such medicines from the market.
- CDSCO maintains that NSQ findings are batch-specific and do not warrant concerns about other products in the market. Critically evaluate this position from the standpoint of consumer confidence and transparency.
Grounded only in the source report — figures and dates are the source's, not inferred.